Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

27 Dec 2018

• By Sten Stovall

Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.

T-cells — Merck KGaA says deal lets it stay invested in CAR-T field while focusing its R&D efforts • Source: Shutterstock

Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D

More from Strategy

More from Business